Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CING NASDAQ:OKYO NASDAQ:QUCY NASDAQ:UPXI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.64-4.1%$4.77$3.16▼$11.89$62.50M-0.91287,087 shs78,014 shsOKYOOKYO Pharma$1.55+4.7%$1.58$1.34▼$3.35$62.86M0.06171,437 shs45,727 shsQUCYMainz Biomed$1.08-2.7%$1.92$0.30▼$4.93$15.83M2.284.26 million shs581,800 shsUPXIUpexi$0.80-0.7%$0.97$0.54▼$9.12$62.98M-0.291.45 million shs813,486 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate-4.13%+2.20%-3.53%-15.17%-16.70%OKYOOKYO Pharma+4.73%+8.39%0.00%-3.73%-44.44%QUCYMainz Biomed-2.70%-12.20%-25.77%+112.77%+107,999,900.00%UPXIUpexi-0.73%-0.55%+1.29%-42.84%-88.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCINGCingulate$4.64-4.1%$4.77$3.16▼$11.89$62.50M-0.91287,087 shs78,014 shsOKYOOKYO Pharma$1.55+4.7%$1.58$1.34▼$3.35$62.86M0.06171,437 shs45,727 shsQUCYMainz Biomed$1.08-2.7%$1.92$0.30▼$4.93$15.83M2.284.26 million shs581,800 shsUPXIUpexi$0.80-0.7%$0.97$0.54▼$9.12$62.98M-0.291.45 million shs813,486 shs10 Stocks Powering The Next AI Boom The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation. Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCINGCingulate-4.13%+2.20%-3.53%-15.17%-16.70%OKYOOKYO Pharma+4.73%+8.39%0.00%-3.73%-44.44%QUCYMainz Biomed-2.70%-12.20%-25.77%+112.77%+107,999,900.00%UPXIUpexi-0.73%-0.55%+1.29%-42.84%-88.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCINGCingulate 2.50Moderate Buy$27.33489.08% UpsideOKYOOKYO Pharma 2.40Hold$5.67265.59% UpsideQUCYMainz Biomed 1.50ReduceN/AN/AUPXIUpexi 2.33Hold$8.10912.25% UpsideCurrent Analyst Ratings BreakdownLatest QUCY, UPXI, OKYO, and CING Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/24/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)7/17/2026OKYOOKYO Pharma Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)7/13/2026OKYOOKYO Pharma HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$7.00 ➝ $5.007/9/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)7/1/2026UPXIUpexi Cantor FitzgeraldSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetOverweight$2.00 ➝ $1.306/8/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeSell (D-) ➝ Sell (E+)6/8/2026CINGCingulate Ascendiant Capital MarketsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingLower Price TargetBuy$55.00 ➝ $52.005/26/2026CINGCingulate HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.005/22/2026CINGCingulate Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/22/2026UPXIUpexi Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeSell (E+) ➝ Sell (D-)5/19/2026CINGCingulate Roth CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$10.00(Data available from 7/25/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCINGCingulateN/AN/AN/AN/A$0.31 per shareN/AOKYOOKYO PharmaN/AN/AN/AN/A($0.16) per shareN/AQUCYMainz Biomed$537.08K29.48N/AN/A$0.07 per share15.43UPXIUpexi$26.14M2.41N/AN/A$1.01 per share0.79Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCINGCingulate-$22.45M-$4.23N/AN/AN/AN/A-365.15%-158.55%8/18/2026 (Estimated)OKYOOKYO Pharma-$4.71MN/AN/AN/AN/AN/AN/AN/A8/10/2026 (Estimated)QUCYMainz Biomed-$16.21M-$47.60N/AN/AN/AN/AN/AN/AN/AUPXIUpexi-$13.68M-$0.62N/AN/AN/A-874.00%-66.70%-19.56%9/2/2026 (Estimated)Latest QUCY, UPXI, OKYO, and CING EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/18/2026Q2 2026CINGCingulate-$0.63N/AN/AN/A$0.17 millionN/A5/14/2026Q1 2026CINGCingulate-$0.53-$0.95-$0.42-$0.95N/AN/A5/12/2026Q3 2026UPXIUpexi-$0.20-$1.67-$1.47-$1.67$2.90 million$1.05 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCINGCingulateN/AN/AN/AN/AN/AOKYOOKYO PharmaN/AN/AN/AN/AN/AQUCYMainz BiomedN/AN/AN/AN/AN/AUPXIUpexiN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCINGCingulateN/A2.552.55OKYOOKYO PharmaN/AN/AN/AQUCYMainz BiomedN/A2.112.11UPXIUpexi2.961.721.72Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCINGCingulate41.31%OKYOOKYO Pharma2.97%QUCYMainz BiomedN/AUPXIUpexi5.68%Insider OwnershipCompanyInsider OwnershipCINGCingulate5.30%OKYOOKYO Pharma40.46%QUCYMainz Biomed3.10%UPXIUpexi9.00%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCINGCingulate2013.47 million12.76 millionNot OptionableOKYOOKYO Pharma740.56 million24.15 millionNot OptionableQUCYMainz Biomed3014.66 million14.21 millionN/AUPXIUpexi13078.70 million71.62 millionOptionableQUCY, UPXI, OKYO, and CING HeadlinesRecent News About These CompaniesUpexi (NASDAQ:UPXI) Shares Up 0.1% - Time to Buy?July 23 at 1:59 AM | marketbeat.comUpexi Insider Trading Activity | NASDAQ:UPXI | BenzingaJuly 7, 2026 | benzinga.comUpexi Inc: Upexi Partners with Blueprint to Stake Solana Treasury AssetsJune 30, 2026 | finanznachrichten.deUpexi Partners with Blueprint to Stake Solana Treasury AssetsJune 30, 2026 | globenewswire.comUpexi Added to Russell Microcap Index in June 2026 ReconstitutionJune 26, 2026 | quiverquant.comQUpexi Added to the Russell Microcap® IndexJune 26, 2026 | globenewswire.comUpexi, Inc. Announces Pricing of ~$19.5 Million Private Placement of Common StockJune 22, 2026 | globenewswire.comUpexi Shareholders Reelect Board and Ratify AuditorJune 16, 2026 | tipranks.comUPXI Share News TodayMay 19, 2026 | uk.investing.comUpexi (UPXI) Stock Forecast & Price TargetMay 15, 2026 | investing.comUpexi Stock Short Interest Report | NASDAQ:UPXI | BenzingaMay 15, 2026 | benzinga.comUpexi (UPXI) Q3 2026 Earnings TranscriptMay 15, 2026 | fool.comUpexi, Inc. Earnings Call Highlights Crypto-Fueled VolatilityMay 13, 2026 | tipranks.comUpexi Net Loss Balloons to $109 Million on Solana Treasury MarkdownMay 13, 2026 | finance.yahoo.comUpexi Reports Fiscal Third Quarter 2026 Financial ResultsMay 12, 2026 | globenewswire.comUpexi Q3 2026 earnings previewMay 11, 2026 | msn.comUpexi to Present at the LD Micro Invitational XVI Conference on May 17-19May 7, 2026 | globenewswire.comUpexi Provides Periodic Update to its Share Repurchase ProgramMay 6, 2026 | globenewswire.comUpexi to Host Third Quarter 2026 Earnings Call on May 12th at 5:30 p.m. ETMay 5, 2026 | globenewswire.comUpexi to Participate in the Scottsdale Capital Event on April 10-12March 31, 2026 | globenewswire.comUpexi to Participate in Upcoming March Investor ConferencesMarch 3, 2026 | globenewswire.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeQUCY, UPXI, OKYO, and CING Company DescriptionsCingulate NASDAQ:CING$4.64 -0.20 (-4.13%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$4.66 +0.02 (+0.32%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cingulate Inc., a biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of attention deficit/hyperactivity disorder and anxiety in the United States. The company's stimulant medications are CTx-1301 (dexmethylphenidate), which is in phase 3 clinical trial, as well as CTx-1302 (dextroamphetamine), which is in investigational new drug application development for the treatment of attention deficit/hyperactivity disorder intended for children, adolescents, and adults. It also focuses on developing CTx-2103 that is in a formulation stage for the treatment of anxiety. The company was founded in 2012 and is headquartered in Kansas City, Kansas.OKYO Pharma NASDAQ:OKYO$1.55 +0.07 (+4.73%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.56 +0.00 (+0.32%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.OKYO Pharma Limited, a clinical-stage biopharmaceutical company, engages in developing therapeutics for patients suffering from inflammatory eye diseases and ocular pain in the United Kingdom. Its lead preclinical product candidate is OK-101, which is in Phase II clinical trials for the treatment of dry eye disease. The company is also developing OK-201, a bovine adrenal medulla, lipidated-peptide preclinical analogue candidate for the treatment of neuropathic chronic pain. The company was incorporated in 2007 and is headquartered in London, the United Kingdom.Mainz Biomed NASDAQ:QUCY$1.08 -0.03 (-2.70%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$1.10 +0.02 (+1.48%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Mainz Biomed B.V., a molecular genetics cancer diagnostic company, develops in-vitro diagnostic (IVD) and research use only tests for clinical diagnostics in human genetics. It offers ColoAlert, a colorectal cancer screening test; PancAlert, a product candidate for a pancreatic cancer screening test; GenoStrip to detect pathogens in environments on a molecular genetic basis; and research-use-only and IVD tests. The company was founded in 2008 and is based in Mainz, Germany.Upexi NASDAQ:UPXI$0.80 -0.01 (-0.73%) Closing price 07/24/2026 04:00 PM EasternExtended Trading$0.80 +0.00 (+0.47%) As of 07/24/2026 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Upexi, Inc. manufactures and sells various branded products in the health, wellness, pet, beauty, and other markets. The company was formerly known as Grove, Inc. and changed its name to Upexi, Inc. in August 2022. The company was incorporated in 2018 and is headquartered in Clearwater, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 07/20- 07/24 Telecom Earnings Reveal a Sector That Finally Looks Healthier AMD and Cerbras Create A New Blueprint For Hardware Intel Earnings Reveal Whether the Chip Selloff Created a Buy CrowdStrike’s Cerebras Deal Puts Its AI Security Strategy to the Test Defense Earnings Show Readiness Now and Modernization Ahead Freeport McMoRan Post-Earnings: Why Good Enough May Finally Be Good Enough Tesla Just Delivered Record Sales—So Why Did the Stock Sell Off? Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
